Raymond James reiterates Strong Buy rating on Scholar Rock stock ahead of PDUFA date

Scholar Rock (SRRK) faces mixed signals as Raymond James maintained its 'Strong Buy' rating and $53 price target despite recent negative developments. The company reported a Q2 2025 EPS of -$0.98, significantly missing analyst expectations of -$0.66, which led to a premarket stock decline. Additionally, Scholar Rock disclosed FDA inspection observations at third-party CDMO facilities involved in the manufacturing of its key drug candidate, apitegromab, ahead of its September 22nd PDUFA date. While the stock has surged over 330% in the past year, InvestingPro analysis suggests it is overvalued at current levels.

Analysis

Scholar Rock (SRRK) presents a conflicting investment profile, marked by a significant divergence between analyst optimism and recent fundamental headwinds. While Raymond James reiterated its 'Strong Buy' rating and a $53 price target, suggesting substantial upside from its current $34.79 price, the company's operational and financial performance raises concerns. Scholar Rock reported a second-quarter 2025 earnings per share of -$0.98, a material 48.48% miss against analyst expectations of -$0.66, which prompted a decline in premarket trading. Compounding this financial weakness are newly disclosed FDA inspection observations at two third-party manufacturing facilities for its key drug candidate, apitegromab. This introduces a critical layer of regulatory risk ahead of the drug's September 22nd PDUFA date. The stock's valuation is also a point of contention; despite a 330% surge over the past year, signals suggest it may be overvalued at current levels, making it vulnerable to these negative catalysts.

Key Decisions for Investors

• Investors should view the upcoming September 22nd PDUFA date as a major binary event, where the recently disclosed FDA manufacturing observations introduce a significant risk that could override the drug's clinical potential.
• It is crucial to weigh the bullish analyst sentiment, exemplified by Raymond James's $53 price target, against the tangible negative signals, including the substantial Q2 earnings miss and the stock's potentially overvalued status following its recent run-up.
• Given the heightened uncertainty, current holders may consider trimming positions to manage risk ahead of the regulatory decision, while prospective investors should be prepared for significant volatility and a potentially negative outcome related to the manufacturing issues.